PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
PepGen (Nasdaq: PEPG) announced an inducement grant to its newly appointed Senior Vice President of Clinical Development, Steve Han, MD, PhD, MMSc. The grant consists of a non-qualified stock option to purchase 95,000 shares at $4.40 per share, vesting over four years with 25% vesting after one year and the remainder monthly over three years. The grant was made under PepGen's 2024 Inducement Plan and approved by the Compensation Committee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
PepGen (Nasdaq: PEPG) ha annunciato un'offerta di incentivi al suo nuovo Vicepresidente Senior dello Sviluppo Clinico, Steve Han, MD, PhD, MMSc. L'offerta consiste in un'opzione su azioni non qualificata per l'acquisto di 95.000 azioni a 4,40 $ per azione, con un vesting su quattro anni, di cui il 25% dopo un anno e il restante mensilmente su tre anni. L'offerta è stata effettuata nell'ambito del Piano di Incentivi 2024 di PepGen ed è stata approvata dal Comitato per la Compensazione come incentivo materiale all'occupazione, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
PepGen (Nasdaq: PEPG) anunció una concesión de incentivos a su recién nombrado Vicepresidente Senior de Desarrollo Clínico, Steve Han, MD, PhD, MMSc. La concesión consiste en una opción de acciones no calificadas para comprar 95,000 acciones a $4.40 por acción, con un periodo de adquisición de cuatro años, donde el 25% se adquiere después de un año y el resto mensualmente durante tres años. La concesión se realizó bajo el Plan de Incentivos 2024 de PepGen y fue aprobada por el Comité de Compensación como un incentivo material para el empleo de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
PepGen (Nasdaq: PEPG)는 새로 임명된 임상 개발 수석 부사장 Steve Han, MD, PhD, MMSc에게 유인 부여를 발표했습니다. 이 부여는 95,000주를 주당 $4.40에 구매할 수 있는 비자격 주식 옵션으로 구성되며, 4년에 걸쳐 25%는 1년 후에 발생하고 나머지는 3년 동안 매월 발생합니다. 이 부여는 PepGen의 2024 유인 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 고용에 대한 실질적인 유인으로 보상 위원회에 의해 승인되었습니다.
PepGen (Nasdaq: PEPG) a annoncé une attribution de primes à son nouveau Vice-Président Senior du Développement Clinique, Steve Han, MD, PhD, MMSc. Cette attribution consiste en une option d'achat d'actions non qualifiée pour l'acquisition de 95 000 actions au prix de $4,40 par action, avec une acquisition répartie sur quatre ans, dont 25 % après un an et le reste mensuellement pendant trois ans. L'attribution a été faite dans le cadre du Plan d'Incentives 2024 de PepGen et a été approuvée par le Comité de Rémunération comme un incitatif matériel à l'emploi conformément à la Règle de Cotation Nasdaq 5635(c)(4).
PepGen (Nasdaq: PEPG) hat einen Anreizvertrag für seinen neu ernannten Senior Vice President für Klinische Entwicklung, Steve Han, MD, PhD, MMSc, bekannt gegeben. Der Vertrag besteht aus einer nicht qualifizierten Aktienoption zum Kauf von 95.000 Aktien zu 4,40 $ pro Aktie, die über vier Jahre mit 25% nach einem Jahr und der Rest monatlich über drei Jahre vestet. Der Vertrag wurde im Rahmen des Anreizplans 2024 von PepGen erstellt und vom Vergütungsausschuss als wesentlicher Anreiz für die Beschäftigung gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- Successful recruitment of senior executive talent with comprehensive compensation package
- Implementation of structured equity incentive program aligned with long-term retention
- Potential shareholder dilution from new stock options
On November 20, 2024, Dr. Han received a non-qualified stock option grant to purchase 95,000 shares of PepGen’s common stock, par value
This inducement grant was granted outside of PepGen’s stockholder-approved equity incentive plans pursuant to PepGen’s 2024 Inducement Plan, which was adopted by PepGen’s Board of Directors in August 2024. This award was approved by the Compensation Committee of the Board of Directors, which consists entirely of independent directors, as a material inducement to Dr. Han’s entering into employment with PepGen in accordance with Nasdaq Listing Rule 5635(c)(4).
About PepGen
PepGen is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, PepGen is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.
For more information, please visit www.pepgen.com. Follow PepGen on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241121499632/en/
Investor
Dave Borah, CFA
SVP, Investor Relations and Corporate Communications
dborah@pepgen.com
Media
Julia Deutsch
Lyra Strategic Advisory
Jdeutsch@lyraadvisory.com
Source: PepGen Inc.
FAQ
What stock options did PepGen (PEPG) grant to its new SVP of Clinical Development?
When will the PEPG inducement grant options vest for Dr. Steve Han?
What is the exercise price of PepGen's (PEPG) inducement grant options issued on November 20, 2024?
